Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

ault.asp.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Researchers ... in nanoparticle technology that will enable broader and ... other diseases with a simple breath screen. The ... the U.S. Food and Drug Administration (FDA) approval ... of the innovative Nanoparticle Biomarker Tagging device. , ...
(Date:3/25/2015)... , March 25, 2015  18 piglets ... of intense research by scientists in the College of ... and represent a breakthrough in the field of ... in the Department of Animal & Avian Sciences (ANSC) ... in ANSC, successfully produced genome-edited pigs using a ...
(Date:3/25/2015)... , March 25, 2015   Demy-Colton Life ... targeted investor and business development conferences exclusively for the ... is launching the Biotech CEO Summit. ... meeting that brings together biotech industry leaders who are ... and innovation while reaping the rewards of biotech,s new ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2Biotech CEO Summit to Bring Key Biotech Leaders Together in Industry Brain Trust 2
... SAN DIEGO, Nov. 8, 2010 Vet-Stem, Inc. announced ... LTD (AVSC) has been completed which secures Vet-Stem,s third ... veterinarians for treating horses, dog and cats.  AVSC is ... services in Australia, New Zealand and Singapore.   ...
... Savara Inc., an inhalation product development company, today ... Board of Directors. In 1983 Mr. Hawkins ... guided the growth of that organization to over 700 ... largest clinical contract research organizations in the world. Since ...
... ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Biology Technology:Vet-Stem Signs License Agreement With Affiliate in Australia for Veterinary Stem Cells 2Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors 2OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 2OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 3OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 4OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 5OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 6OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 7OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 8OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 9
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... with environmental threats like bad weather, predators or oil ... researchers have analyzed blood samples to detect corticosterone levels ... have shown that corticosterone spikes can also be detected ... in the May 11 online edition of " Journal ...
... From hot pink to traditional French and Lady Gaga,s sophisticated ... But they are not just pretty when nails appeared ... million years ago, they led to the development of critical ... the ability to grasp, whether it,s a nail polish brush ...
... has seeded the Salk Institute as the number one research ... plant biologists, Joe Ecker, Ph.D., Joanne Chory, Ph.D. Jeff Long, ... the number of highly cited papers with the most impact, ... world with the greatest number of highly cited papers (top ...
Cached Biology News:A tool to measure stress hormone in birds -- feathers 2Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3Salk Institute named global leader in plant biology research 2
... form of cell suicide, which follows a ... of this process is a cascade of ... participate in a series of reactions that ... and result in the cleavage of protein ...
...
...
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Biology Products: